A study on Ozempic’s impacts on Alzheimer’s disease didn’t have the results scientists hoped for. We talk to UNLV’s Dr. Jeffrey Cummings on the research and what’s next. Also from UNLV: a look at how a “new” species of an ancient human ancestor can help shape our view on evolution. We end with a fun story on “Silver Belle”... the first tree from Nevada to serve as the U.S. Capitol Christmas Tree!

A study on Ozempic’s impacts on Alzheimer’s disease didn’t have the results scientists hoped for. We talk to UNLV’s Dr. Jeffrey Cummings on the research and what’s next. Also from UNLV: a look at how a “new” species of an ancient human ancestor can help shape our view on evolution. We end with a fun story on “Silver Belle”... the first tree from Nevada to serve as the U.S. Capitol Christmas Tree!

Over the past few years, scientists have learned that Ozempic and related drugs developed to treat Type 2 diabetes can improve the health of the liver, kidney and heart. Is it such a stretch to think they could also treat neurological disorders? Perhaps — at least when it comes to Alzheimer’s disease.

Alzheimer's patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to new data presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting.

Detailed results from the phase 3 EVOKE and EVOKE+ trials of the oral GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) in early Alzheimer’s disease (AD) have been presented. The initial negative topline results announced last week by the company were met with disappointment in the AD research community, but the newly presented biomarker data offer some grounds for optimism and may point to a potential path forward.

Details from two large trials of Novo Nordisk's NOVOb.CO GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wednesday, dashing remaining hopes that the widely used medication could help such patients.

When Herriot Tabuteau launched his drug development company, Axsome Therapeutics, in 2012, he decided to do things differently by focusing on treatments for brain disorders that are particularly challenging to develop. Now, he’s sitting on a $6 billion empire, according to Forbes.

Detect Alzheimer's disease early with a groundbreaking blood test that could change the game for millions of people worldwide! This revolutionary diagnostic tool can identify the disease years before symptoms appear, giving patients and their families a head start on treatment and care. The FDA just cleared the first blood test for identifying patients with amyloid pathology associated with Alzheimer’s disease — and part of the research behind its approval was conducted by leading experts at the UNLV Department of Brain Health, with chair and renowned brain health researcher, Jefferson Kinney, PhD, our guest for today’s Show. In this video, we'll dive into the science behind this innovative test, how it works, and what it means for the future of Alzheimer's research and treatment. If you or a loved one is at risk for Alzheimer's, you won't want to miss this!

In the United States, 12% of adults have taken a glucagon-like peptide 1 (GLP-1) antagonist. The drugs aren’t just popular for weight loss; 62% of adults taking semaglutide or other GLP-1 drugs take them for chronic conditions, such as diabetes and heart disease — and dementia could be added to that list.

The gunman who killed four people in Midtown Manhattan claims in a suicide note that he wanted his brain to be studied for CTE, the degenerative brain disease associated with repeated hits to the head. Chronic Traumatic Encephalopathy, also known as CTE, has been found in former National Football League and National Hockey League players, boxers, and members of the military.

Shane Tamura, the Las Vegas man responsible for a New York City shooting that left 4 dead, blamed football and the NFL for his perceived struggle with the neurodegenerative disease chronic traumatic encephalopathy (CTE).

A new blood test is being called a game changer for helping diagnose Alzheimer’s. The new FDA-approved test, known as Lumipulse, detects the pTau217/Beta Amyloid 42 amyloids plaques in the brain, a hallmark of the disease.